In previous studies, cancer treatment targeting ferroptosis has mainly been limited to solute carrier family 7a member 11 (SLC7A11) and GPX4, and currently, therapies targeting ferritinophagy receive increasing attention [66, 69, 70]. Here, GPX4 is linked to cancer.